Roth Capital Keeps Stemline (STML) at 'Buy'; Still Plenty to See and Do in 2014
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $62 target price on Stemline Therapeutics (Nasdaq: STML) following the company's Q1 results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
